SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 4, 1994
BIOMET, INC.
(Exact Name of Registrant as specified in its charter)
Indiana 0-12515 35-1418342
(State or Other Jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Airport Industrial Park, P. O. Box 587, Warsaw, IN 46581-0587
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 1-219-267-6639
Not Applicable
(Former name or former address, if changed since last report.)
Item 2. Acquisition or Disposition of Assets.
The merger of Kirschner Medical Corporation ("Kirschner")
with and into Kirschner Acquisition Corp. ("KAC"), a wholly-owned
subsidiary of the Company pursuant to an Agreement and Plan of
Merger by and among Biomet, Inc. (the "Company"), Kirschner and
Biomet Acquisition Corp. ("BAC"), dated July 16, 1994, which was
subsequently amended by a First Amendment to Agreement and Plan
of Merger by and among the Company, Kirschner, BAC and KAC, dated
September 15, 1994, was approved by a majority of the
shareholders of Kirschner and consummated on November 4, 1994.
The merger became effective at 12:01 a.m. on November 5, 1994
(the "Effective Time").
On November 4, 1994, the Company delivered $16,245,980.50
and 1,384,309 Common Shares of the Company to Bankers Trust
Company, the Exchange Agent. At the Effective Time the existence
of Kirschner ceased and KAC and Kirschner began existence as a
wholly-owned subsidiary of the Company, operating under the name
"Kirschner Medical Corporation."
Kirschner's business and operations of its facilities will
continue in the manufacturing and marketing of total joint
reconstruction products and surgical instrumentation and
orthopedic support products.
Item 7. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
It is impracticable to provide the required financial
statements with this filing. The financial statements
of the acquired business will be filed on or before
January 17, 1995.
(b) Pro forma financial information.
It is impracticable to provide the required pro forma
financial information with this filing. The pro forma
financial information will be filed on or before
January 17, 1995.
(c) Exhibits
See Index to Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOMET, INC.
Date: November 18, 1994 /s/ Dane A. Miller
_____________________________________
Dane A. Miller
President and Chief Executive Officer
BIOMET, INC.
FORM 8-K
INDEX TO EXHIBITS
Exhibit Number Page Number in
Assigned in Sequential
Regulation S-K Numbering
Item 601 Description of Exhibit System
______________ ______________________ ______________
(1) No Exhibit.
(2) 2.01 Agreement and Plan of Merger by and
among Biomet, Inc., Biomet Acquisition
Corp. and Kirschner Medical Corporation.
(Incorporated by reference to Exhibit 2
to Schedule 13D filed August 20, 1994, by
Biomet, Inc. and Kirschner Acquisition
Corporation with respect to the Common
Stock, $0.01 par value, of Kirschner,
CUSIP No. 497660100.)
2.02 First Amendment to Agreement and Plan of
Merger by and among Biomet, Inc., Biomet
Acquisition Corp., Kirschner Acquisition
Corp. and Kirschner Medical Corporation.
(Incorporated by reference to Exhibit 2.02
to Biomet's Amendment No. 1 to Form S-4,
Registration No. 33-55483.)
(4) No Exhibit.
(16) No Exhibit.
(17) No Exhibit.
(20) Not Exhibit.
(23) 23.01 Consent of KPMG Peat Marwick LLP.*
(24) No Exhibit.
(27) 27.01 Financial Data Schedule.*
* To be filed by Amendment
